3SBio lays groundwork for $500m Hong Kong IPO
3SBio Inc, a biotech firm based in China, is looking to raise $400m-$500m from an IPO in Hong Kong, in what would be its second outing as a listed concern after delisting from Nasdaq in 2013.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts